Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.365 USD | -3.19% | -12.50% | -48.30% |
Apr. 08 | Transcript : Cue Biopharma, Inc., Q4 2023 Earnings Call, Apr 08, 2024 | |
Apr. 08 | North American Morning Briefing : Inflation Data, -2- | DJ |
Business Summary
Number of employees: 53
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Injectable Biologics
100.0
%
| 1 | 100.0 % | 5 | 100.0 % | +340.88% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 1 | 100.0 % | 5 | 100.0 % | +340.88% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Daniel Passeri
CEO | Chief Executive Officer | 63 | 16-07-31 |
Anish Suri
PSD | President | 50 | 18-06-30 |
Kerri-Ann Millar
DFI | Director of Finance/CFO | 54 | 17-08-31 |
Matteo Levisetti
CTO | Chief Tech/Sci/R&D Officer | 55 | 21-02-21 |
Marie Campinell
IRC | Investor Relations Contact | - | - |
Colin Sandercock
LAW | General Counsel | 67 | 17-11-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Fred Driscoll
BRD | Director/Board Member | 74 | 18-06-25 |
Daniel Passeri
CEO | Chief Executive Officer | 63 | 16-07-31 |
Peter Kiener
BRD | Director/Board Member | 72 | 16-02-29 |
Frank Morich
CHM | Chairman | 69 | 18-08-02 |
Patrick Verheyen
BRD | Director/Board Member | 64 | 23-04-10 |
Pamela Garzone
BRD | Director/Board Member | 69 | 23-04-18 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 48,643,316 | 47,197,910 ( 97.03 %) | 0 | 97.03 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-48.30% | 66.4M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- CUE Stock
- Company Cue Biopharma, Inc.